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Glutamate
The	important	neuro-protective	and	neuro-physiologi-
cal	role	of	glutame	started	to	be	under	concideration	in	
1930,	when	high	concentrations	of	it	were	recognised	
for	 the	 first	 time	 in	 the	 brain.	 It	was	 this	 ascertain-
ment	 that	 ten	years	 later	 led	scientists	 to	use	dietary	
glutamate	 and	 glutamine	 for	 learning	 disorders	 and	
epilepsy	treatment.
In	1952	Hayashi	noticed	convulsions	in	carotid	ar-
teries	and	in	 the	brain	after	glutamate	infusion.	This	
was	the	first	time	that	glutamate	was	considered	as	a	
CNS	neurotransmitter1.	
Despite	all	of	the	above,	it	was	not	up	until	the	late	
70’s	that	glutamate	was	widely	accepted	as	the	main	
neurotransmitter	of	the	vertebrate	nervous	system.
At	the	same	time,	it	was	suggested	that	glutamate	
action	is	due	to	its	metasynaptic	action	in	three	fami-
lies	 of	 ionotropic	 receptors,	 named	 after	 their	 ago-
nists:	 N-methyl-D-asparate	 (NMDA)2,	 A-amino-3-
hydroxy-5-methyl-4-isoxazolepropionicacid	(AMPA)	
and	kainate.
Quite	interesting	is	the	fact	that	glutamate	binding	
sites	at	their	ionotropic	receptors	seem	to	present	a	ho-
mologous	 sequence	with	 periplasmic	 bacteria	 trans-
mitters	as	well	as	with	plant	peptides	pointing	out	the	
long	evolutionary	path	of	glutamate	receptors3.
In	our	days	we	are	familiar	with	the	fact	that	glu-
tamate	 is,	 along	with	aspartate,	one	of	 the	main	en-
dogenous	acids	in	CNS,	and	glutamate	with	its	recep-
tors	are	involved	in	a	wide	range	of	physiological	and	
pathological	activities	such	as:
-	 Memory	and	learning	process4
-	 Neuron	development	and	synaptogenesis5
-	 Alzheimer’s	disease6
-	 Epilepsy7
Glutamate receptors
The	process	of	glutamate	acting	as	a	transmitter	among	
cells	involves	certain	phases	of	activity.	The	transmit-
ter	is	«packed»	in	vesicles	and	is	therefore	ready	to	be	
released	when	a	stimulus	arrives.	After	the	exocytosis	
of	the	vesicles	the	transmitter	is	diffused	in	the	syn-
aptic	gap	in	order	to	be	uptaken	by	the	metasynaptic	
receptors.	Receptors’	activation	provokes	a	series	of	
changes	at	the	metasynaptic	cell8.	Glutamate	is	acting	
upon	metasynaptic	 receptors,	 even	 though	 there	 are	
also	prosynaptic	receptors.
The	presence	of	many	different	types	of	receptors	
allows	a	single	agonist,	in	our	case	glutamate,	to	acti-
vate	many	different	ways	of	transmission.
Glutamate’s	 receptors	 are	 classified	 in	 two	 large	
categories:
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-	 ionotropic	receptors	acting	as	ion	channels
-	 metabotropic	receptors	connected	with	intracellu-
lar	messengers9.
IonotropIc Glutamate receptors
Ionotropic	glutamate	receptors	are	ion	channels	medi-
ating	in	the	last	majority	of	excitatory	neurotransmi-
tion	in	the	brain.	Up	to	today	there	have	been	cloned	
20	 different	 sudunits	 of	 glutamate	 ionotropic	 recep-
tors	from	primary	mammals.
Based	on	their	agonists	they	are	pharmacological-
ly	classified	in	those	activated	by	the	synthetic	agonist	
N-methyl-D-asparate	 (NMDA),	 and	 those	character-
ized	by	 their	affinity	 to	 the	 synthetic	agonist	AMPA	
and	kainate	natural	neurotoxin10.
Glutamate	ionotropic	receptor	subunits	are	coded	
by	 at	 least	 6	 gene	 families	 (3	 for	NMDA	 receptors,	
one	for	AMPA	and	2	for	kainate).
The	sequence	homology	suggests	a	mutual	starting	
point	 of	 evolution	 as	 far	 as	 ionotropic	 receptors	 are	
concerned.
i. NMDA receptors
NMDA	 receptors	 are	mainly	 located	 at	 CNS’s	 syn-
apsis	 and	are	 composed	by	NR1	and	NR2	subunits.	
Each	 receptor	 is	 considered	 as	 a	 structure	 of	 2NR1	
and	2NR2	subunits
3	gene	families	code	6	sudunits	of	NMDA	recep-
tors	(NR1,	NR2A-3D,	NR3A)11.
The	 uniqueness	 of	 an	 NMDA	 receptor	 is	 deter-
mined	by	the	NR2	subunit,	NR2A-D.
The	same	subunit	refers	to	the	time	needed	in	or-
der	for	the	receptor	to	open	the	channel	and	answer	to	
different	kind	of	antagonists.
NR2B	subunits,	for	example,	refer	to	slow	kinetics,	
whereas	NR2A	ones	refer	to	high	kinetics	of	the	struc-
turel2.	Each	receptor	has	a	number	of	specific	binding	
sites	for	agonists,	antagonists	and	other	modulators.
NMDA’s	receptor	specific	characteristic	is	its	need	
for	glycine	as	a	co-agonist	for	the	activation	of	the	ion	
channel.
As	a	 result,	 every	 receptor	has	 two	binding	 sites	
for	glycine	and	two	binding	sites	for	glutamate13.	This	
binding	site	is	provided	by	NR1	subunit14.
ii. Kainate receptors
Kainate	acid	receptors	are	fewest	compared	to	gluta-
mate	receptors	as	a	total.
Kainate	 is	 one	 of	 the	 most	 potent	 neurotoxin	
known,	 and	 to	 be	more	 precise	 it	 is	 50	 times	more	
potent	compared	to	glutamate	as	far	as	CNS	neurons	
depolarizing	is	concerned.
Kainate	subunits	are	olomeric	and	eteromeric	com-
plexes	of	GluR5-GluR7,	KA1	and	KA2	subunits15.
Like	AMPA	 receptors	 they	 can	mediate	 high	 ki-
netic	excitatory	stimuli,	and	they	are	also	involved	in	
neurotrasmitter	 prosynaptic	 release	 therefore	 also	 in	
the	synaptic	connection	force16.
ampa receptors
As	far	as	neurons	are	concerned	the	transmission	and	
conclusion	of	neuronal	stimuli	is	under	the	control	of	
a	 receptor	 ion	 channel.	Among	 those	 receptors	 and	
of	 great	 importance	 are	AMPA	 receptors,	 omo	 and	
eteromeric	complexes	consisting	of	GluR
1
-GluR
4
	sub-
units17.
AMPA	receptors	are	tetrameric,	permeable	only	in	
sodium	due	to	GluR2	subunit18.	Even	though	the	last	
2	types	of	inonotropic	glutamate	receptors	do	not	have	
the	same	molecular	constitution	and	have	a	different	
affinity	 concerning	 their	 agonists	 and	 co-agonists,	
AMPA	and	kainate	 receptors	 are	 usually	 considered	
as	a	funcional	entity	(non-NMDA	receptors),	based	on	
the	fact	that	the	substances	modulating	their	function	
do	not	seem	to	have	a	preferance	towards	one	or	an-
other	type	of	receptor19.
In	conclusion,	when	comparing	the	three	types	of	
ionotropic	glutame	receptors	one	should	have	in	mind	
that	NMDA	receptors	are	activated	more	powerfully	
by	glutamate,	whereas	non-NMDA	receptors	are	acti-
vated	and	inactivated	faster.
The	 fact	 that	AMPA	 receptors	 are	 inactivated	10	
times	faster	than	the	others,	makes	it	possible	for	them	
to	maintain	their	activated	form.	As	a	result,	when	an	
excitatory	stimulus	is	transmitted	through	the	synap-
tic	gap,	with	glutamate	as	the	nuerotransmitter,	AMPA	
are	the	first	receptors	to	be	activated.	The	membrane	
potential	conducted	that	way	in	the	metasynaptic	neu-
ron	 inhibits	 NMDA	 receptor	 blockage	 induced	 by	
Mg2+	 and	 consequently,	 glutamate	 activates	 NMDA	
receptors20.
metaBotropIc Glutamate receptors
Over	the	last	10	years	it	has	become	well	known	that	
glutamate	can	play	a	regulatory	role	 through	the	ac-
	 Glutamate	Receptors	in	Blood	Elements	and	Bone	Marrow	Megakaryocytes	 39
tivation	of	 receptors	connected	with	a	 second	group	
of	messengers,	the	metabotropic	receptors	(mGluRs);	
mGluRs	 are	 part	 of	 a	 large	 family	 of	 proteins	with	
seven	 transmembrane	 sites	 and	 have	 been	 classified	
in	3	subgroups	based	on	their	homologous	sequence,	
their	 pharmacological	 characteristics,	 and	 their	 con-
nection	with	second	messengers.
The	first	subgroup	includes	subunits	mGluR1	and	
mGluR5,	subgroup	II	includes	subunits	mGluR2,3	and	
subgroup	III	subunits	mGluR4,6,7,821.
Glutamate’s	 metabotropic	 receptors’	 activation	
leads	 to	 several	 cell	 responses	 such	 as	 the	 enhance-
ment	of	Ca2+	and	K+	ion,	the	prosynaptic	alteration	of	
the	stimulus	transfer	and	the	prosynaptic	co-reaction	
with	glutamic	acid’s	ionotropic	receptors.
It	is	worth	mentioning	that	in	many	CNS	areas	the	
answer	to	exogenous	NMDA	infusion	is	due	to	first’s	
mGluRs	subgroup	activation22.
Glutamate and perIpheral tIssues
It	was	a	little	after	the	establishment	of	the	importance	
of	glutamate	and	its	receptors	for	CNS	function	that	
scientists	started	exploring	the	possibility	of	those	re-
ceptors	 being	 encounted	 in	 peripheral	 non-neuronal	
tissues.
PT-PCR,	PCR,	Nothern	Blots,	Western	Blots,	imu-
nohistochemistry	and	in	situ	hibridism	were	used	with	
remarkable	results.
In	our	days	we	are	familiar	with	the	fact	that	gluta-
mate’s	receptors	are	present	in	many	peripheral	tissues	
such	as	adrenal	medulla23,	peripheral	nerves,	myelin-
ated	and	unmyelinated	nerves24,25,	bone26-35	endocrine	
pancreas36-41	 esophagus42,	 hepatocytes43,44,	 heart45,46,	
taste	 buds47,48,	 keratinocytes46,	 lungs49,50,51	 pituitary52,	
pineal	gland53,	ileal	longitudinal	muscle54-56,	autonom-
ic	and	sensory	ganglia57,	kidney,	spleen,	ovaries42,	and	
stomach58.
Last	but	not	 least,	glutamate	receptors	have	been	
found	 in	 peripheral	 blood	 elements	 and	 in	 the	 bone	
marow	cells.
All	 of	 the	 above	 suggest	 that	 glutamate	 act	 as	 a	
widespread	cytokine,	 that	can	affect	cell	 function	 in	
various	peripheral	tissues	outside	CNS.
Glutamate and t-cells
T-cells	 can	 encounter	 neurotransmitters	 in	 different	
parts	 of	 our	 body	 such	 as	 lymphoid	 organs,	 blood,	
peripheral	nervous	system	and	Central	Nervous	Sys-
tem.
Furthermore,	 in	 autoimmune	diseases	 like	multi-
ple	Sclerosis,	where	T-cell	are	of	an	important	role	in	
myelin	sheath,	 they	attack	 the	neurotransmitters	and	
T-cells	interact	with	them.
Even	though	molecules	used	for	intraimmune	and	
intranervous	communication	are	different,	many	types	
of	neuroimmune	interaction	have	been	reported59,60.
As	a	result,	most	of	the	literature	about	glutamate	
and	hematopoietic	system	concern	mainly	T-cells.
Konstayan’s	 et	 al61	 studies	 on	 immune	 system	
showed	the	presence	of	glutamate	binding	sites	on	hu-
man	lymphocyte	surface.	The	following	studies	were	
expanded	on	rodents.	In	rodents,	it	has	been	found	that	
there	are	subgroups	I	and	II	of	metabotropic	receptors	
in	thymus,	isolated	thymus	cells,	thymic	stromal	cell	
line62.
Subgroup	III	of	metabotropic	 receptors	and	NR1	
subunit	of	NMDA	ionotropic	receptors	can	be	found	
in	recently	isolated	lymphocytes63.
As	far	as	humans	are	concerned	GluR3	subunits	of	
AMPA	ionotropic	 receptors	have	been	 found	on	Pe-
ripheral	T-Cells,	in	Jurkot	T	leukaimic	cell	line	and	in	
a	CD4	alloprimed	T-helper	clone64.
Group	I	of	metabotropic	receptors	have	also	been	
found	in	both	active	and	non-active	T-cells	as	well	as	
in	several	lymphoid	series65,66.
Recently,	G.	Miglio	et	 al	have	 suggested	 the	ex-
pression	of	sudunits’	NR1	and	NR2	genes	in	human	
cells.	 In	 fact	 the	presence	of	 the	NMDA	receptor	 in	
human	 lymphocytes	 was	 found	 to	 be	 familiar	 with	
that	of	CNS’s67.
Up	to	today,	it	has	been	found	that	glutamate	alone	
(without	the	presence	of	other	stimulating	molecules)	
in	direct	interaction	with	it’s	AMPA	receptors	triggers	
integrin-mediated	adhesion	to	laminin	and	fibronectin	
something	only	seen	in	activated	cells.
Moreover,	 glutamate	 was	 found	 to	 regulate	 the	
CXCR4-mediated	 T	 cell	 chemotactic	 migration	 to-
ward	 the	 key	 chemokine	 CXCL12/stromal	 cell-de-
rived	factor-1	encounted	both	in	CNS	and	in	periph-
eral	 tissues	 and	being	 of	 an	 important	 part	 in	many	
immune	and	neural	functions64.
Recently	 research	 showed	 that	 MK-801,	 a	 non-
competitive	 NMDA	 antagonist,	 inhibited	 PHA-in-
duced	T	cell	proliferation	of	 resting	T-cells	 (and	not	
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that	of	T	blasts)		in	a	concentration	depended	manner	
without	modifing	cell	viability	or	cell	death.The	same	
antagonist	 inhibited	 mitogen	 induced	 cell	 prolifera-
tion		suggesting	that	NMDA	antagonists	affect	T-cells’	
activation67.
Glutamate and meGakaryocytes
There	 are	 not	 many	 papers	 published	 concerning	
glutamate,	 its	 receptors	 and	 their	 relationship	 with	
megakaryocytes,	nevertheless	the	results	existing,	are	
enough	 to	 show	another	gap	 in	our	knowledge	con-
cerning	glutamate’s	action	outside	CNS.
Research	proved	the	presence	of	NR1	and	NR2D	
subunits	 in	 human	 and	 rat	 megakaryocytes	 as	 well	
as	 in	MEG-01	cell	 line68.	 In	human	megakaryocytes	
there	 are	 also	NR2A	subunits	 as	well	 as	Yotaio	 and	
PSD-95	 helping	 protein69	 both	 important	 for	 intra-
cellular	 and	 cytoplasmic	 membrane	 changes,	 when	
NMDA	receptor	 is	 activated70,71.	The	 absence	of	 the	
rest	of	the	proteins	related	with	CNS’	NMDA	receptor	
is	just	underlying	the	fact	that	those	receptors	may	be	
similar	but	are	definately	not	identical.
Another	 interesting	 observation	 is	 that	 glycosili-
osis	level	in	megakaryocyte’s	receptos	is	less	or	even	
absent	when	compared	to	that	of	CNS’	receptors68.
All	those	differences	mentioned	above	may	be	due	
to	the	diffent	use	of	the	receptors.
The	 first	 clue	 that	 glutamate	 is	 affecting	 mega-
karyocytes	 and	 maybe	 megakaryocytopoiesis	 and	
platelet	release,	was	the	ascertainment	that	glutamate	
that	PMA	 induced	differentation	of	MEG-01	blastic	
cell	line	to	a	more	megakaryocytic	phenotype,	which	
includes	increase	in	cell	size,	cell	adhesin	(cell	to	cell,	
and	cell	to	matrix),	and	the	expression	of	surface	anti-
gen	CD41a	was	inhibited	with	MK-801	presence	68.
Glutamate and platelets 
In	1996,	Fanconi	et	al	proved	 that	glutamate	has	an	
anti-aggregating	 activity	 on	 platelets,	 primaly	 ex-
posed	to	arachidonic	acid	or	ADP	or	platelet	aggregat-
ing	factor	(PAF)72.
Platelet	 glutamate	 subunit	 receptors	 are	 in	 some	
ways	 different	 compared	 with	 CNS’	 receptors.	 For	
example,	when	it	comes	to	platelets,	the	presence	of	
glutamate	 or	 glycine73,74	 (together	 or	 each	 by	 itself)	
has	no	effect	on	[3H]-MK-801	binding,	whereas	it	has	
a	smoothing	affect	with	the	maximun	effect	being	no-
ticed	in	the	presence	of	both.
Furthermore,	 NMDA’s	 anti-agreggating	 activity	
is	 affected	 in	 a	 negative	way	 by	 unusual	 high	 con-
centrations	of	non-competitive	antagonist	MK-80175,	
whereas	 competitive	 antagonist	AP5	 has	 absolutely	
no	affect	at	all.
All	of	the	above	led	to	the	conclusion	that	platelet	
receptors	has	a	selective	affinity	to	their	agonists.
Later	 expirements	 showed	 that	 NMDA	 receptor	
activation	(either	by	NMDA	or	by	glutamic	acid	with	
the	first	being	3	times	more	powerfull	than	the	later)	
is	antagonising	the	aggregating	activity	of	arachidonic	
acid	in	human	rich	platelet	plasma,	while	there	is	no	
aggregating	action,	neither	from	NMDA	nor	from	glu-
tamate.
NMDA	had	no	effect	in	the	u-46619	induced	ag-
gregation,	 which	 shows	 that	 glutamate’s	 action	 has	
nothing	to	do	with	TxA2/ΠGH2	receptors	on	platelets.	
In	addition,	it	antagonizes	the	ADP	and	PAF	induced	
platelet	aggregation,	and	when	combined	either	with	
aspirin	or	with	indomethacin	it	increases	their	anti-ag-
gregating	activity.
Finaly,	 NMDA	 raised	 cAMP’s	 levels	 in	 intact	
platelets	and	this	was	not	reversed	by	calmodulin	tri-
fluoparazine	inhibitor	(TFP)76.
conclusIon
All	of	the	papers	mentioned	above	point	out	that	glu-
tamate	 receptors	 play	 an	 important	 role	 on	 T-cells,	
platelets,	and	bone	marrow	megakaryocytes	function.
There	are	still	questions	to	be	answered	concern-
ing	the	possible	use	of	the	glutamate	receptors	in	the	
cure	of	haematopoietic	diseases,	and	puzzling	minds	
on	their	use	on	patients	with	co-existing	neurological	
and	haematopoietic	disorders.
Further	research	is	needed	so,	as	to	define	the	im-
portance	of	glutamate	receptors	presence	in	peripheral	
blood	elements,	and	in	bone	marrow	cells	and,	how	it	
affects	haematopoietic	system	in	vivo.
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